← Back to Search

Checkpoint Inhibitor

RTX-240 for Acute Myeloid Leukemia

Phase 1 & 2

Waitlist Available

Research Sponsored by Rubius Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 38 months

Awards & highlights

Study Summary

This trial is testing a new medication, RTX-240, for treating cancer either alone or with another medication, pembrolizumab. It is open to people who have tried other treatments and either didn't respond or their disease got worse.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 38 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 38 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 38 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicities (DLTs) of study treatment as determined by incidence and severity of adverse events (AEs)

Safety Assessment: Measured by incidence of Treatment Emergent Adverse Events (TEAEs)

Secondary outcome measures

Anti-Tumor activity of study treatment Measured by Objective Response Rate (ORR)

Anti-tumor activity of study treatment measured by clinical benefit rate (CBR) (% of patients who achieve CR, PR or stable disease [SD])

Anti-tumor activity of study treatment measured by duration of response (DoR)

+7 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Trial Design

4Treatment groups

Experimental Treatment

Group I: Part 4: RTX-240 Plus Pembrolizumab Dose EscalationExperimental Treatment2 Interventions

Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors

Group II: Part 3: RTX-240 Dose EscalationExperimental Treatment1 Intervention

Phase 1: RTX-240 monotherapy dose escalation in AML

Group III: Part 2: RTX-240 Solid Tumor ExpansionExperimental Treatment1 Intervention

Phase 2: RTX-240 monotherapy dose expansion in Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and anal cancers

Group IV: Part 1: RTX-240 Dose EscalationExperimental Treatment1 Intervention

Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rubius TherapeuticsLead Sponsor

3 Previous Clinical Trials

17 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any unfilled slots in this clinical investigation?

"At this point in time, no participants are being recruited for the trial. Initially posted on May 6th 2020 and edited as recently as September 26th 2022, alternative studies may be worth exploring; presently 1 study is accepting patients with solid tumors or acute myeloid leukemia while 961 trials require RTX-240 volunteers."

Answered by AI

Are there a variety of venues conducting this experiment in the city?

"This study is presently taking place in 11 different medical centers, located across New york, Miami and Fairfax. Prospective participants should choose the closest clinic to minimize travel requirements."

Answered by AI

Has RTX-240 been subjected to other empirical investigations?

"RTX-240 was first evaluated a decade ago by City of Hope. To date, 251 studies have concluded while 961 ongoing trials are being administered in New york City and beyond."

Answered by AI

What medical indications is RTX-240 usually recommended for?

"RTX-240 is used to combat malignant neoplasms, unresectable melanomas, and microsatellite instability high diseases."

Answered by AI

How many participants have been accepted into the experiment so far?

"As of now, this clinical trial is not actively recruiting new patients. Initially posted on May 6th 2020 and most recently updated on September 26th 2022, there are other trials which may be suitable for you; namely 1 study involving solid tumor research and 961 studies in relation to RTX-240 enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

RTX-240 Monotherapy and in Combination With Pembrolizumab

2020. "RTX-240 Monotherapy and in Combination With Pembrolizumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04372706.